Epoetin alfa as an adjuvant to autologous blood donation.
The development of anemia is one factor that can limit the donation of sufficient autologous blood (AB) to meet a patient's expected blood requirements following elective orthopedic surgery. Two clinical studies have been conducted in nonanemic patients to investigate the use of epoetin alfa as an adjuvant to AB predonation to facilitate AB procurement and minimize the development of anemia. Both studies demonstrated that patients with a normal hematocrit (Hct) can donate > or = 3 units of AB prior to surgery. However, treatment with epoetin alfa minimized the decrease in Hct associated with AB donation. While there was a trend toward a reduction in allogeneic blood exposure in patients treated with epoetin alfa, the difference relative to placebo was not significant. This observation may be explained by a limited requirement for blood in this patient population that was met by predonation of 3 AB units. Thus, the use of epoetin alfa as an adjunct to AB predonation is likely to be of most benefit in patients with a normal Hct scheduled for surgical procedures where the expected blood requirements exceed 3 units. In addition, epoetin alfa may enable patients with a low Hct, low body weight, or low predicted blood volume to participate in or to complete an AB donation program, thus reducing the possibility of exposure to allogeneic blood.
Beris
P
P
Hôpital Cantonal, University of Geneva, Switzerland.
D000740:Anemia / Q000517:prevention & control; D001803:Blood Transfusion / Q000706:statistics & numerical data; D001804:Blood Transfusion, Autologous / Q000706:statistics & numerical data; D004305:Dose-Response Relationship, Drug; D000068817:Epoetin Alfa; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage / Q000494:pharmacology*; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007501:Iron / Q000008:administration & dosage; D009985:Orthopedics; D011292:Premedication; D011994:Recombinant Proteins; D016896:Treatment Outcome
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa; D007501:Iron